title: 5-day nonobserved artesunate monotherapy for treating uncomplicated Falciparum malaria in young Gabonese children.
abstract: Despite different recommendations from WHO and national authorities, artesunate monotherapy is increasingly used for treating African children with malaria. A 5-day course of oral artesunate (first day: 4 mg/kg body weight, observed intake; and 2 mg/kg body weight on the following days with nonobserved drug intake) yielded a PCR-corrected Day 28 cure rate of 90% (45 of 50 patients; CI 78-97%) in Gabonese children aged between 2 and 18 months. Artesunate was well tolerated, and no severe adverse events were reported.
authors.affiliation: Medical Research Unit, Albert Schweitzer Hospital Lambaréné, Gabon.
authors.forename: Norbert G
authors.initials: NG
authors.lastname: Schwarz
authors.forename: Sunny
authors.initials: S
authors.lastname: Oyakhirome
authors.forename: Marc
authors.initials: M
authors.lastname: Pötschke
authors.forename: Benjamin
authors.initials: B
authors.lastname: Gläser
authors.forename: Peter
authors.initials: P
authors.lastname: Klein Klouwenberg
authors.forename: Handan
authors.initials: H
authors.lastname: Altun
authors.forename: Ayola A
authors.initials: AA
authors.lastname: Adegnika
authors.forename: Saadou
authors.initials: S
authors.lastname: Issifou
authors.forename: Jürgen F J
authors.initials: JF
authors.lastname: Kun
authors.forename: Peter G
authors.initials: PG
authors.lastname: Kremsner
authors.forename: Martin P
authors.initials: MP
authors.lastname: Grobusch
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D037621:Artemisinins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077332:Artesunate; D005260:Female; D005681:Gabon; D006801:Humans; D007223:Infant; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D018512:Parasitemia / Q000188:drug therapy / Q000469:parasitology; D010963:Plasmodium falciparum / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D012717:Sesquiterpenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D012717:Sesquiterpenes; D000077332:Artesunate